79 results on '"Bergami F"'
Search Results
2. Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM)
- Author
-
Pedrazzoli, P., Lasagna, A., Cassaniti, I., Ferrari, A., Bergami, F., Silvestris, N., Sapuppo, E., Di Maio, M., Cinieri, S., and Baldanti, F.
- Published
- 2022
- Full Text
- View/download PDF
3. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
- Author
-
Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Alessio, N., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Secondino, S., Cicognini, D., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., and Cassaniti, I.
- Published
- 2022
- Full Text
- View/download PDF
4. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up
- Author
-
Lasagna, A., Lilleri, D., Agustoni, F., Percivalle, E., Borgetto, S., Alessio, N., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Secondino, S., Falzoni, M., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., and Cassaniti, I.
- Published
- 2022
- Full Text
- View/download PDF
5. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
- Author
-
Lasagna, A., Agustoni, F., Percivalle, E., Borgetto, S., Paulet, A., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Lilleri, D., Secondino, S., Falzoni, M., Schiavo, R., Klersy, C., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., and Cassaniti, I.
- Published
- 2021
- Full Text
- View/download PDF
6. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
- Author
-
Bruno, R, Mondelli, M, Brunetti, E, Di Matteo, A, Seminari, E, Maiocchi, L, Zuccaro, V, Pagnucco, L, Mariani, B, Ludovisi, S, Lissandrin, R, Parisi, A, Sacchi, P, Patruno, SFA, Michelone, G, Gulminetti, R, Zanaboni, D, Novati, S, Maserati, R, Orsolini, P, Vecchia, M, Sciarra, M, Asperges, E, Colaneri, M, Di Filippo, A, Sambo, M, Biscarini, S, Lupi, M, Roda, S, Pieri, TC, Gallazzi, I, Sachs, M, Valsecchi, P, Perlini, S, Alfano, C, Bonzano, M, Briganti, F, Crescenzi, G, Falchi, AG, Guarnone, R, Guglielmana, B, Maggi, E, Martino, I, Pettenazza, P, Pioli di Marco, S, Quaglia, F, Sabena, A, Salinaro, F, Speciale, F, Zunino, I, De Lorenzo, M, Secco, G, Dimitry, L, Cappa, G, Maisak, I, Chiodi, B, Sciarrini, M, Barcella, B, Resta, F, Moroni, L, Vezzoni, G, Scattaglia, L, Boscolo, E, Zattera, C, Tassi, MF, Capozza, V, Vignaroli, D, Bazzini, M, Iotti, G, Mojoli, F, Belliato, M, Perotti, L, Mongodi, S, Tavazzi, G, Marseglia, G, Licari, A, Brambilla, I, Barbarini, D, Bruno, A, Cambieri, P, Campanini, G, Cavanna, C., Comolli, G, Corbella, M, Daturi, R, Furione, M, Marone, P, Monzillo, E, Paolucci, S, Parea, M, Percivalle, E, Piralla, A, Rovida, F, Sarasini, A, Zavattoni, M, Adzasehoun, G, Ardizzone, M, Bellotti, L, Brunco, V, Cabano, E, Casali, G, Capella, L, Devitis, D, Dossena, L, Frisco, G, Garbagnoli, G, Gardellini, F, Girello, A, Guerrizio, A, Landini, V, Lucchelli, C, Maliardi, V, Piemontese, P, Pezzaia, S, Premoli, M, Rebuffa, C, Zanello, C, Bagnarino, J, Bergami, F, Bonetti, A, Caneva, G, Cassaniti, I, Corcione, A, Di Martino, R, Di Napoli, A, Ferrari, A, Ferrari, G, Fiorina, L, Gallone, A, Giardina, F, Girardi, A, Mercato, A, Merla, C, Novazzi, F, Ratano, G, Rossi, B, Saveriaempillai, G, Sciabica, IM, Tallarita, M, Vecchio Nepita, E, Vitali, J, Cerino, A, Varchetta, S, Oliviero, B, Mantovani, S, Mele, D, Calvi, M, Tizzoni, M, Nicora, C, Triarico, A, Petronella, V, Marena, C, Muzzi, A, Lago, P, Cutti, S, Novelli, V, Comandatore, F, BatistiBiffignandi, G, Gaiarsa, S, Rettani, M, Bandi, C, Paolucci, Stefania, Cassaniti, Irene, Novazzi, Federica, Fiorina, Loretta, Piralla, Antonio, Comolli, Giuditta, Bruno, Raffaele, Maserati, Renato, Gulminetti, Roberto, Novati, Stefano, Mojoli, Francesco, and Baldanti, Fausto
- Published
- 2021
- Full Text
- View/download PDF
7. Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine in vulnerable patients with giant cell arteritis
- Author
-
Delvino, P, Bartoletti, A, Cassaniti, I, Bergami, F, Lilleri, D, Baldanti, F, Bozzalla Cassione, E, Biglia, A, Montecucco, C, Monti, S, Delvino P., Bartoletti A., Cassaniti I., Bergami F., Lilleri D., Baldanti F., Bozzalla Cassione E., Biglia A., Montecucco C., Monti S., Delvino, P, Bartoletti, A, Cassaniti, I, Bergami, F, Lilleri, D, Baldanti, F, Bozzalla Cassione, E, Biglia, A, Montecucco, C, Monti, S, Delvino P., Bartoletti A., Cassaniti I., Bergami F., Lilleri D., Baldanti F., Bozzalla Cassione E., Biglia A., Montecucco C., and Monti S.
- Published
- 2022
8. Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis
- Author
-
Monti, S, Fornara, C, Delvino, P, Bartoletti, A, Bergami, F, Comolli, G, Sammartino, J, Biglia, A, Cassione, E, Cassaniti, I, Baldanti, F, Lilleri, D, Montecucco, C, Sammartino, JC, Cassione, EB, Monti, S, Fornara, C, Delvino, P, Bartoletti, A, Bergami, F, Comolli, G, Sammartino, J, Biglia, A, Cassione, E, Cassaniti, I, Baldanti, F, Lilleri, D, Montecucco, C, Sammartino, JC, and Cassione, EB
- Abstract
Objectives. To analyse humoral and cellular immune response to mRNA COVID-19 vaccines in patients with GCA. Methods. Consecutive patients with a diagnosis of GCA receiving two doses of BNT162b2 vaccine were assessed at baseline and 3 weeks from the second vaccine dose. Healthy subjects (n 1⁄4 51) were included as controls (HC). Humoral response was assessed with Spike-specific IgG antibody response (S-IgG) and neutralizing antibodies (NtAb). Specific T cell response was assessed by enzyme linked immunosorbent spot (ELISpot). Results. Of 56 included patients with GCA, 44 were eligible after exclusion of previous evidence of COVID-19 and incomplete follow-up. A significant proportion of patients with GCA (91%) demonstrated antibody (S-IgG) response, but this was significantly lower than HCs (100%); P < 0.0001. Neutralizing activity was not detected in 16% of patients with GCA. Antibody titres (S-IgG and NtAb) were significantly lower compared with HCs. Humoral response (S-IgG and NtAb) was significantly hampered by treatment with MTX. Cellular response was lacking in 30% of patients with GCA (vs 0% in HCs; P < 0.0001). Cellular response was significantly influenced by the levels of baseline peripheral T-lymphocytes and by glucocorticoid treatment. Treatment with tocilizumab did not affect any level of the immune response elicited by vaccination. Conclusions. Although patients with GCA apparently achieve a robust antibody seroconversion, there is a significant impairment of the neutralizing activity. MTX significantly reduced all levels of the humoral response. Up to one-third of patients do not develop a cellular immune protection in response to COVID-19 vaccination.
- Published
- 2023
9. Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment
- Author
-
Lasagna, A., primary, Bergami, F., additional, Lilleri, D., additional, Percivalle, E., additional, Quaccini, M., additional, Comolli, G., additional, Sarasini, A., additional, Sammartino, J.C., additional, Ferrari, A., additional, Arena, F., additional, Cicognini, D., additional, Schiavo, R., additional, Lo Cascio, G., additional, Baldanti, F., additional, Pedrazzoli, P., additional, and Cassaniti, I., additional
- Published
- 2022
- Full Text
- View/download PDF
10. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
- Author
-
Paolucci, Stefania, primary, Cassaniti, Irene, additional, Novazzi, Federica, additional, Fiorina, Loretta, additional, Piralla, Antonio, additional, Comolli, Giuditta, additional, Bruno, Raffaele, additional, Maserati, Renato, additional, Gulminetti, Roberto, additional, Novati, Stefano, additional, Mojoli, Francesco, additional, Baldanti, Fausto, additional, Bruno, R, additional, Mondelli, M, additional, Brunetti, E, additional, Di Matteo, A, additional, Seminari, E, additional, Maiocchi, L, additional, Zuccaro, V, additional, Pagnucco, L, additional, Mariani, B, additional, Ludovisi, S, additional, Lissandrin, R, additional, Parisi, A, additional, Sacchi, P, additional, Patruno, SFA, additional, Michelone, G, additional, Gulminetti, R, additional, Zanaboni, D, additional, Novati, S, additional, Maserati, R, additional, Orsolini, P, additional, Vecchia, M, additional, Sciarra, M, additional, Asperges, E, additional, Colaneri, M, additional, Di Filippo, A, additional, Sambo, M, additional, Biscarini, S, additional, Lupi, M, additional, Roda, S, additional, Pieri, TC, additional, Gallazzi, I, additional, Sachs, M, additional, Valsecchi, P, additional, Perlini, S, additional, Alfano, C, additional, Bonzano, M, additional, Briganti, F, additional, Crescenzi, G, additional, Falchi, AG, additional, Guarnone, R, additional, Guglielmana, B, additional, Maggi, E, additional, Martino, I, additional, Pettenazza, P, additional, Pioli di Marco, S, additional, Quaglia, F, additional, Sabena, A, additional, Salinaro, F, additional, Speciale, F, additional, Zunino, I, additional, De Lorenzo, M, additional, Secco, G, additional, Dimitry, L, additional, Cappa, G, additional, Maisak, I, additional, Chiodi, B, additional, Sciarrini, M, additional, Barcella, B, additional, Resta, F, additional, Moroni, L, additional, Vezzoni, G, additional, Scattaglia, L, additional, Boscolo, E, additional, Zattera, C, additional, Tassi, MF, additional, Capozza, V, additional, Vignaroli, D, additional, Bazzini, M, additional, Iotti, G, additional, Mojoli, F, additional, Belliato, M, additional, Perotti, L, additional, Mongodi, S, additional, Tavazzi, G, additional, Marseglia, G, additional, Licari, A, additional, Brambilla, I, additional, Barbarini, D, additional, Bruno, A, additional, Cambieri, P, additional, Campanini, G, additional, Cavanna, C., additional, Comolli, G, additional, Corbella, M, additional, Daturi, R, additional, Furione, M, additional, Marone, P, additional, Monzillo, E, additional, Paolucci, S, additional, Parea, M, additional, Percivalle, E, additional, Piralla, A, additional, Rovida, F, additional, Sarasini, A, additional, Zavattoni, M, additional, Adzasehoun, G, additional, Ardizzone, M, additional, Bellotti, L, additional, Brunco, V, additional, Cabano, E, additional, Casali, G, additional, Capella, L, additional, Devitis, D, additional, Dossena, L, additional, Frisco, G, additional, Garbagnoli, G, additional, Gardellini, F, additional, Girello, A, additional, Guerrizio, A, additional, Landini, V, additional, Lucchelli, C, additional, Maliardi, V, additional, Piemontese, P, additional, Pezzaia, S, additional, Premoli, M, additional, Rebuffa, C, additional, Zanello, C, additional, Bagnarino, J, additional, Bergami, F, additional, Bonetti, A, additional, Caneva, G, additional, Cassaniti, I, additional, Corcione, A, additional, Di Martino, R, additional, Di Napoli, A, additional, Ferrari, A, additional, Ferrari, G, additional, Fiorina, L, additional, Gallone, A, additional, Giardina, F, additional, Girardi, A, additional, Mercato, A, additional, Merla, C, additional, Novazzi, F, additional, Ratano, G, additional, Rossi, B, additional, Saveriaempillai, G, additional, Sciabica, IM, additional, Tallarita, M, additional, Vecchio Nepita, E, additional, Vitali, J, additional, Cerino, A, additional, Varchetta, S, additional, Oliviero, B, additional, Mantovani, S, additional, Mele, D, additional, Calvi, M, additional, Tizzoni, M, additional, Nicora, C, additional, Triarico, A, additional, Petronella, V, additional, Marena, C, additional, Muzzi, A, additional, Lago, P, additional, Cutti, S, additional, Novelli, V, additional, Comandatore, F, additional, BatistiBiffignandi, G, additional, Gaiarsa, S, additional, Rettani, M, additional, and Bandi, C, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit
- Author
-
Colaneri, M., Seminari, E., Novati, S., Asperges, E., Biscarini, S., Piralla, A., Percivalle, E., Cassaniti, I., Baldanti, F., Bruno, R., Mondelli, M. U., Brunetti, E., Di Matteo, A., Maiocchi, L., Zuccaro, V., Pagnucco, L., Ludovisi, S., Lissandrin, R., Parisi, A., Sacchi, P., Patruno, S. F. A., Michelone, G., Gulminetti, R., Zanaboni, D., Maserati, R., Orsolini, P., Vecchia, M., Di Filippo, A., Sambo, M., Lupi, M., Roda, S., Pieri, T. C., Gallazzi, I., Sachs, M., Valsecchi, P., Perlini, S., Alfano, C., Bonzano, M., Briganti, F., Crescenzi, G., Falchi, A. G., Guarnone, R., Guglielmana, B., Maggi, E., Martino, I., Pettenazza, P., di Marco, S. P., Quaglia, F., Sabena, A., Salinaro, F., Speciale, F., Zunino, I., de Lorenzo, M., Secco, G., Dimitry, L., Cappa, G., Maisak, I., Chiodi, B., Sciarrini, M., Barcella, B., Resta, F., Moroni, L., Vezzoni, G., Scattaglia, L., Boscolo, E., Zattera, C., Fidel, T. M., Vincenzo, C., Vignaroli, D., Bazzini, M., Iotti, G., Mojoli, F., Belliato, M., Perotti, L., Mongodi, S., Tavazzi, G., Marseglia, G., Licari, A., Brambilla, I., Barbarini, D., Bruno, A., Cambieri, P., Campanini, G., Cavanna, C., Comolli, G., Corbella, M., Daturi, R., Furione, M., Mariani, B., Marone, P., Monzillo, V., Paolucci, S., Parea, M., Rovida, F., Sarasini, A., Zavattoni, M., Adzasehoun, G., Ardizzone, M., Bellotti, L., Brunco, V., Cabano, E., Casali, G., Capella, L., Devitis, D., Dossena, L., Frisco, G., Garbagnoli, G., Gardellini, F., Girello, A., Guerrizio, A., Landini, V., Lucchelli, C., Maliardi, V., Piemontese, P., Pezzaia, S., Premoli, M., Rebuffa, C., Bagnarino, J., Bergami, F., Bonetti, A., Caneva, G., Corcione, A., Di Martino, R., Di Napoli, A., Ferrari, A., Ferrari, G., Fiorina, L., Gallone, A., Giardina, F., Girardi, A., Mercato, A., Novazzi, F., Ratano, G., Rossi, B., Saverimpilla, G., Sciabica, I. M., Tallarita, M., Nepita, E. V., Vitali, J., Cerino, A., Varchetta, S., Oliviero, B., Mantovani, S., Mele, D., Calvi, M., Tizzoni, M., Nicola, C., Triarico, A., Petronella, V., Marena, C., Muzzi, A., Lago, P., Comandatore, F., Biffignandi, G. B., Gaiarsa, S., Rettani, M., and Bandi, C.
- Subjects
0301 basic medicine ,Microbiology (medical) ,Environmental contamination ,medicine.medical_treatment ,030106 microbiology ,Microbiology ,Coronavirus disease 2019 ,Severe acute respiratory syndrome coronavirus-2 ,Surfaces ,Vero E6 cells ,Animals ,Betacoronavirus ,Chlorocebus aethiops ,Coronavirus Envelope Proteins ,Equipment Contamination ,Fomites ,Humans ,Intensive Care Units ,Microbial Viability ,RNA-Dependent RNA Polymerase ,Reverse Transcriptase Polymerase Chain Reaction ,SARS-CoV-2 ,Vero Cells ,Viral Envelope Proteins ,Viral Proteins ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,RNA polymerase ,medicine ,030212 general & internal medicine ,Continuous positive airway pressure ,Respiratory system ,Gene ,Cytopathic effect ,business.industry ,RNA ,General Medicine ,Infectious Diseases ,chemistry ,Vero cell ,business - Abstract
Objectives To detect possible severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) RNA contamination of inanimate surfaces in areas at high risk of aerosol formation by patients with coronavirus disease 2019 (COVID-19). Methods Sampling was performed in the emergency unit and the sub-intensive care ward. SARS-CoV-2 RNA was extracted from swabbed surfaces and objects and subjected to real-time RT-PCR targeting RNA-dependent RNA polymerase and E genes. Virus isolation from positive samples was attempted in vitro on Vero E6 cells. Results Twenty-six samples were collected and only two were positive for low-level SARS-CoV-2 RNA, both collected on the external surface of continuous positive airway pressure helmets. All transport media were inoculated onto susceptible cells, but none induced a cytopathic effect on day 7 of culture. Conclusions Even though daily contact with inanimate surfaces and patient fomites in contaminated areas may be a medium of infection, our data obtained in real-life conditions suggest that it might be less extensive than hitherto recognized.
- Published
- 2020
- Full Text
- View/download PDF
12. Tocilizumab for treatment of severe covid-19 patients: Preliminary results from smatteo covid19 registry (smacore)
- Author
-
Colaneri, M., Bogliolo, L., Valsecchi, P., Sacchi, P., Zuccaro, V., Brandolino, F., Montecucco, C., Mojoli, F., Giusti, E. M., Bruno, R., Mondelli, M. U., Brunetti, E., Di Matteo, A., Seminari, E., Maiocchi, L., Pagnucco, L., Ludovisi, S., Lissandrin, R., Parisi, A., Patruno, S. F. A., Michelone, G., Gulminetti, R., Zanaboni, D., Novati, S., Maserati, R., Orsolini, P., Vecchia, M., Asperges, E., Di Filippo, A., Sambo, M., Biscarini, S., Lupi, M., Roda, S., Chiara Pieri, T., Gallazzi, I., Sachs, M., Perlini, S., Alfano, C., Bonzano, M., Briganti, F., Crescenzi, G., Giulia Falchi, A., Guarnone, R., Guglielmana, B., Maggi, E., Martino, I., Pettenazza, P., Di Marco, S. P., Quaglia, F., Sabena, A., Salinaro, F., Speciale, F., Zunino, I., De Lorenzo, M., Secco, G., Dimitry, L., Cappa, G., Maisak, I., Chiodi, B., Sciarrini, M., Barcella, B., Resta, F., Moroni, L., Vezzoni, G., Scattaglia, L., Boscolo, E., Zattera, C., Fidel, T. M., Vincenzo, C., Vignaroli, D., Bazzini, M., Iotti, G., Maurelli, M., Mongodi, S., Tavazzi, G., Belliato, M., Perotti, L., Aliberti, A. R., Amatu, A., Anfossi, L., Arisi, E., Baldi, C., Bellini, L., Benzi, A., Bichisao, G., Bolongaro, A., Andrea, B., Federica, B., Giacomo, B., Luca, C., Emanuele, C., Valeria, C., Fabrizio, C., Maria, C., Maria Paola, D., Elisa Lucia, D., Federica, F., Fiorenza, F., Marta, F., Marinella, F., Maddalena Margherita, G., Simonetta, G., Marcella, I., Claudia, L. C., Giuseppe, M., Benedetta, M. M., Simonetta, M., Maria, M. P., Maria, M. A., Federica, M., Larissa, N. T., Silvano, N., Anita, O., Michele, P., Debora, P., Simona, P., Raffaella, P., Silvia, P., Marco, P., Emanuela, P., Roberta, P., Danila Katia, R., Gianluca, R., Filippo, R., Francesca, R., Roberto, R., Giuseppe, R., Emanuela, R., Cristina, R., Giuseppe, S. G., Fabio, S., Debora, S., Giulia, T., Federico, V., Silvia, Z., Alessandro, B., Corrado, B., Chiara, B., Andrea, C., Costanza, C., Julia, N., Valentino, D., Roberto, D., Adelaide, G. M., Filippo, G., Andrea, P., Cecilia, Q., Andrea, S., Francesco, T., Chiara, D., Francesco, E., Bruno, L., Elisa, M., Maria Chiara, R., Barbara, R., Mariangela, S., Monica, T., Federica, V., Roberto, V., Marseglia, G., Licari, A., Brambilla, I., Baldanti, F., Barbarini, D., Bruno, A., Campanini, G., Cavanna, C., Comolli, G., Corbella, M., Daturi, R., Furione, M., Mariani, B., Marone, P., Paolucci, S., Parea, M., Percivalle, E., Piralla, A., Rovida, F., Sarasini, A., Zavattoni, M., Piero, M., Cambieri, P., Monzillo, V., Ardizzone, M., Bellotti, L., Brunco, V., Cabano, E., Casali, G., Capella, L., Devitis, D., Dossena, L., Frisco, G., Garbagnoli, G., Gardellini, F., Girello, A., Guerrizio, A., Landini, V., Lucchelli, C., Maliardi, V., Piemontese, P., Pezzaia, S., Premoli, M., Rebuffa, C., Bagnarino, J., Bergami, F., Bonetti, A., Caneva, G., Cassaniti, I., Corcione, A., Di Martino, R., Di Napoli, A., Ferrari, A., Ferrari, G., Fiorina, L., Gallone, A., Giardina, F., Girardi, A., Mercato, A., Novazzi, F., Ratano, G., Rossi, B., Saverimpilla, G., Sciabica, I. M., Tallarita, M., Nepita, E. V., Vitali, J., Cerino, A., Varchetta, S., Oliviero, B., Mantovani, S., Mele, D., Calvi, M., Tizzoni, M., Nicora, C., Triarico, A., Petronella, V., Marena, C., Muzzi, A., Lago, P., Cutti, S., Novelli, V., Comandatore, F., Biffignandi, G. B., Gaiarsa, S., Rettani, M., and Bandi, C.
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Azithromycin ,Off label therapy ,Microbiology ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Tocilizumab ,Virology ,Internal medicine ,Propensity score matching ,Medicine ,030212 general & internal medicine ,COVID-19 pneumonia ,Adverse effect ,lcsh:QH301-705.5 ,030203 arthritis & rheumatology ,business.industry ,Mortality rate ,Hydroxychloroquine ,medicine.disease ,Pneumonia ,chemistry ,lcsh:Biology (General) ,Cohort ,ICU ,tocilizumab ,off label therapy ,propensity score matching ,mortality rate ,business ,medicine.drug - Abstract
Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19.
- Published
- 2020
13. Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy
- Author
-
Novazzi, Federica, Cassaniti, Irene, Piralla, Antonio, Di Sabatino, Antonio, Bruno, Raffaele, Baldanti, Fausto, Mondelli, M, Brunetti, E, Di Matteo, A, Seminari, E, Maiocchi, L, Zuccaro, V, Pagnucco, L, Mariani, B, Ludovisi, S, Lissandrin, R, Parisi, A, Sacchi, P, Patruno, SFA, Michelone, G, Gulminetti, R, Zanaboni, D, Novati, S, Maserati, R, Orsolini, P, Vecchia, M, Sciarra, M, Asperges, E, Colaneri, M, Di Filippo, A, Sambo, M, Biscarini, S, Lupi, M, Roda, S, Pieri, TC, Gallazzi, I, Sachs, M, Valsecchi, P, Perlini, S, Alfano, C, Bonzano, M, Briganti, F, Crescenzi, G, Falchi, AG, Guarnone, R, Guglielmana, B, Maggi, E, Martino, I, Pettenazza, P, Pioli di Marco, S, Quaglia, F, Sabena, A, Salinaro, F, Speciale, F, Zunino, I, De Lorenzo, M, Secco, G, Dimitry, L, Cappa, G, Maisak, I, Chiodi, B, Sciarrini, M, Barcella, B, Resta, F, Moroni, L, Vezzoni, G, Scattaglia, L, Boscolo, E, Zattera, C, Tassi, MF, Capozza, V, Vignaroli, D, Bazzini, M, Iotti, G, Mojoli, F, Belliato, M, Perotti, L, Mongodi, S, Tavazzi, G, Marseglia, G, Licari, A, Brambilla, I, Barbarini, D, Bruno, A, Cambieri, P, Campanini, G, Cavanna, C, Comolli, G, Corbella, M, Daturi, R, Furione, M, Marone, P, Monzillo, E, Paolucci, S, Parea, M, Percivalle, E, Rovida, F, Sarasini, A, Zavattoni, M, Adzasehoun, G, Ardizzone, M, Bellotti, L, Brunco, V, Cabano, E, Casali, G, Capella, L, Devitis, D, Dossena, L, Frisco, G, Garbagnoli, G, Gardellini, F, Girello, A, Guerrizio, A, Landini, V, Lucchelli, C, Maliardi, V, Piemontese, P, Pezzaia, S, Premoli, M, Rebuffa, C, Zanello, C, Bagnarino, J, Bergami, F, Bonetti, A, Caneva, G, Corcione, A, Di Martino, R, Di Napoli, A, Ferrari, A, Ferrari, G, Fiorina, L, Gallone, A, Giardina, F, Girardi, A, Mercato, A, Ratano, G, Rossi, B, Saveriaempillai, G, Sciabica, IM, Tallarita, M, Vecchio Nepita, E, Vitali, J, Cerino, A, Varchetta, S, Oliviero, B, Mantovani, S, Mele, D, Calvi, M, Tizzoni, M, Nicora, C, Triarico, A, Petronella, V, Marena, C, Muzzi, A, Lago, P, Cutti, S, Novelli, V, Comandatore, F, Batisti Biffignandi, G, Gaiarsa, S, Rettani, M, and Bandi, C
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,education ,Immunology ,medicine.disease_cause ,SARS‐CoV‐2 ,Covid‐19 in Children and Adolescents ,03 medical and health sciences ,2020 Update from The Italian Society of Pediatric Allergy and Immunology ,0302 clinical medicine ,COVID‐19 ,Internal medicine ,Epidemiology ,transmission routes ,medicine ,Immunology and Allergy ,030212 general & internal medicine ,Pediatrics, Perinatology, and Child Health ,Coronavirus ,swabs ,specimen types ,northern Italy ,business.industry ,SARS-CoV-2 ,COVID-19 ,medicine.disease ,epidemiology ,Northern italy ,Pneumonia ,030228 respiratory system ,Respiratory secretion ,Nasal Swab ,Pediatrics, Perinatology and Child Health ,Supplement Article ,business - Abstract
Coronavirus disease 2019 (COVID‐19) diagnosis is based on molecular detection of SARS‐CoV‐2 in respiratory samples such as nasal swab (NS) However, the evidence that NS in patients with pneumonia was sometimes negative raises the attention to collect other clinical specimens SARS‐CoV‐2 was shown in 10 3% rectal swabs (RS), 7 7% plasma, 1% urine, and 0% feces from 143 NS‐positive patients Potential infection by fluids different from respiratory secretion is possible but unlikely [ABSTRACT FROM AUTHOR] Copyright of Pediatric Allergy & Immunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission However, users may print, download, or email articles for individual use This abstract may be abridged No warranty is given about the accuracy of the copy Users should refer to the original published version of the material for the full abstract (Copyright applies to all Abstracts )
- Published
- 2020
14. The Efficacy of Intensive Short Term Dynamic Psychotherapy for Anxiety Disorders when provided by Psychologists in training
- Author
-
Rocco, Diego, Abbass, A., Agrosì, V., Bergami, F., Busetto, L. M., Marin, S., Pezzetta, G., Rossi, L., Zuccotti, L., and Zanelli, D.
- Subjects
short term psychotherapy ,ISTDP ,outcome evaluation - Published
- 2014
15. Microsurgical treatment of varicocele in children: Preliminary report of 25 cases
- Author
-
Fabbrini, G., Bagolan, P., Ciprandi, G., Riccardi, C., Inglese, R., Cappa, M., and Bergami, F.
- Published
- 1989
- Full Text
- View/download PDF
16. Esophageal atresia: critical review of 10 years' experience
- Author
-
Rivosecchi, M., Bagolan, P., Matarazzo, E., Alessandri, A., Ferro, F., Dall' Oglio, L., Federici, G., Ponticelli, A., and Bergami, F.
- Published
- 1989
- Full Text
- View/download PDF
17. Valutazione dell’efficacia della ISTDP (Intensive Short Term Dynamic Psychotherapy) su pazienti con disturbo d’ansia
- Author
-
Rocco, Diego, Agrosì, V., Bergami, F., Busetto, L. M., Marin, S., Pezzetta, G., Rossi, L., Zuccotti, L., Zanelli, D., and Pettenon, A.
- Subjects
process-outcome research ,Short-term psychotherapy - Published
- 2013
18. Valutazione dell’efficacia della ISTDP (Intensive Short Term Dynamic Psy-chotherapy) applicata da giovani specializzati del CISSPAT su pazienti con disturbo d’ansia
- Author
-
Rocco, Diego, Agrosì, V., Bergami, F., Busetto, L. M., Marin, S., Pezzetta, G., Rossi, L., Zuccotti, L., and Zanelli, D.
- Subjects
Psicoterapia Dinamica breve ,Disturbo d'ansia ,Valutazione esiti - Published
- 2013
19. Valutazione dell’efficacia della ISTDP (intensive short term dynamic psychothe-rapy) su pazienti con disturbo d’ansia
- Author
-
Rocco, Diego, Agrosì, V., Bergami, F., Busetto, L. M., Marin, S., Pezzetta, G., Rossi, L., Zuccotti, L., and Zanelli, D.
- Subjects
outcome evaluation ,Short-term psychotherapy - Published
- 2012
20. Emergenze Toraciche
- Author
-
Alamanni F, Ancona E, Anselmino M, Beltrami V, Bergami F, Biglioli P, Boglino C, Bonavina L, Brazzi L, Cappelletti M, Carretta A, Castagnone D, Chiesa G, Ciprandi G, Cortale M, Di Nuzzo D, Donin I, Fedriga E, Floriani M, Gattinoni L, Gherli T, Giulini SM, Grossi A, Guglielmi M, Inserra A, Leggeri A, Liguori G, Lovaria A, Lubatti L, Messineo A, Pelosi P, Peracchia A, Pouchè A, Pozzato C, Rossi P, Sottini A, Stipa S, Tiberio G, Tiberio GAM, Trazzi R, Volterrani F, Ziparo V., DOCIMO, Ludovico, Alamanni, F, Ancona, E, Anselmino, M, Beltrami, V, Bergami, F, Biglioli, P, Boglino, C, Bonavina, L, Brazzi, L, Cappelletti, M, Carretta, A, Castagnone, D, Chiesa, G, Ciprandi, G, Cortale, M, Di Nuzzo, D, Docimo, Ludovico, Donin, I, Fedriga, E, Floriani, M, Gattinoni, L, Gherli, T, Giulini, Sm, Grossi, A, Guglielmi, M, Inserra, A, Leggeri, A, Liguori, G, Lovaria, A, Lubatti, L, Messineo, A, Pelosi, P, Peracchia, A, Pouchè, A, Pozzato, C, Rossi, P, Sottini, A, Stipa, S, Tiberio, G, Tiberio, Gam, Trazzi, R, Volterrani, F, and Ziparo, V.
- Published
- 2000
21. Structural characterization of a synaptic adhesion complex
- Author
-
Ranaivoson, F.M., primary, Liu, Q., additional, Martini, F., additional, Bergami, F., additional, von Daake, S., additional, Li, S., additional, Lee, D., additional, Demeler, B., additional, Hendrickson, W.A., additional, and Comoletti, D., additional
- Published
- 2015
- Full Text
- View/download PDF
22. Crystal structure of the Olfactomedin domain of latrophilin 3 in C2221 crystal form
- Author
-
Ranaivoson, F.M., primary, Liu, Q., additional, Martini, F., additional, Bergami, F., additional, Von daake, S., additional, Li, S., additional, Demeler, B., additional, Hendrickson, W.A., additional, and Comoletti, D., additional
- Published
- 2015
- Full Text
- View/download PDF
23. Crystal structure of the Olfactomedin domain of latrophilin 3 in P65 crystal form
- Author
-
Ranaivoson, F.M., primary, Liu, Q., additional, Martini, F., additional, Bergami, F., additional, Von daake, S., additional, Li, S., additional, Demeler, B., additional, Hendrickson, W.A., additional, and Comoletti, D., additional
- Published
- 2015
- Full Text
- View/download PDF
24. Aspetti delle indicazioni al trattamento nel reflusso gastro esofageo
- Author
-
Dall'Oglio, L., Rivosecchi, M., Ferro, F., Ponticelli, A., Bagolan, P., Caterino, Salvatore, and Bergami, F.
- Published
- 1982
25. Le anomalie delle strutture paratesticolari nei pazienti criptorchidi
- Author
-
Ferro, F., Caterino, Salvatore, Inserra, A., Menichella, P., and Bergami, F.
- Subjects
undescended testis ,epididymal abnormalities - Published
- 1985
26. Il criptorchidismo
- Author
-
Bergami, F., Caterino, Salvatore, and Ferro, F.
- Published
- 1986
27. The citrate method of phosphoric acid determination, with special reference to insoluble phosphates
- Author
-
Bergami, F., primary
- Published
- 1895
- Full Text
- View/download PDF
28. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
- Author
-
Lasagna A, Mele D, Bergami F, Alaimo D, Dauccia C, Alessio N, Comolli G, Pasi F, Muzzi A, Novelli V, Baldanti F, Pedrazzoli P, and Cassaniti I
- Subjects
- Humans, Herpesvirus 3, Human, Pilot Projects, Prospective Studies, Adjuvants, Immunologic, Glycoproteins, Vaccination, Vaccines, Synthetic adverse effects, Herpes Zoster Vaccine, Herpes Zoster prevention & control, Neoplasms drug therapy
- Abstract
Herpes zoster (HZ) is caused by the reactivation of latent varicella zoster virus (VZV). Severe immunocompromising conditions, such as solid tumors, have been largely associated with an increased risk for HZ due to waning VZV-specific cellular immunity. With the approval of the adjuvanted glycoprotein E (gE)-based recombinant vaccine (RZV; Shingrix™, GSK) also in immunocompromised subjects, HZ is considered a vaccine-preventable disease changing perspectives in immunocompromised subjects. To date, no clinical trial has evaluated the immunogenicity in the patients with cancer undergoing immunotherapy. In this study, we describe the humoral and cell-mediated immune responses in 38 cancer patients treated with immune checkpoint inhibitors (ICIs) and receiving RZV. We used samples collected at baseline (T0), 3 weeks (T2), and 6 months (T3) after the complete RV vaccination schedule. Our data showed that a significant proportion (40,5%) of RZV recipients mounted a stronger humoral and cell-mediated immune response at 3 weeks (T2) after complete RZV vaccination schedule. Interestingly, both humoral and cell-mediated immune responses were mostly stable over 6 months (T3). Interestingly, the overall IFNγ-producing lymphocytes was mainly associated with CD4 T cell response ( p = .0012). In conclusion, data from our pilot study suggest a strong and long-lasting immunogenicity of RZV in ICI-treated patients. Prospective analyses at 1 year after vaccination will be performed in order to evaluate the long-term persistence of humoral and cell-mediated response against RZV.
- Published
- 2023
- Full Text
- View/download PDF
29. An overview of SARS-CoV-2 variants circulating in the 2020-2022 period in Lombardy.
- Author
-
Giardina F, Ferrari G, Zavaglio F, Paolucci S, Rovida F, Campanini G, Pellegrinelli L, Galli C, Pariani E, Bergami F, Nava A, Matarazzo E, Renica S, Fanti D, Cento V, Alteri C, Scaglione F, Vismara C, Perno CF, Piralla A, and Baldanti F
- Subjects
- Humans, Spike Glycoprotein, Coronavirus genetics, Disease Outbreaks, SARS-CoV-2 genetics, COVID-19 epidemiology
- Abstract
Since the beginning of the pandemic, SARS-CoV-2 has shown genetic variability. All the variants that have sustained pandemic waves have shown several mutations, especially in the Spike protein that could affect viral pathogenesis. A total of 15,729 respiratory samples, collected between December 2020 and August 2022, have been included in this study. We report the circulation of SARS-CoV-2 variants in the Lombardy region, Italy, in a 2-year study period. Alpha, Delta, and Omicron variants became predominant causing the majority of cases whereas Beta or Gamma variants mostly caused local outbreaks. Next-generation sequencing revealed several mutations and few deletions in all of the main variants. For example, 147 mutations were observed in the Spike protein of Omicron sublineages; 20% of these mutations occurred in the receptor-binding domain region., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
30. Early Postnatal Infection of Neonates Born to Mothers Infected by SARS-CoV-2 Omicron Variant.
- Author
-
Pietrasanta C, Ronchi A, Agosti M, Mangili G, Sinelli M, Ghirardello S, Barachetti R, Crimi R, Fasolato V, Martinelli S, Bellan C, Crippa B, Artieri G, Perniciaro S, Saruggia M, Ventura ML, Garofoli F, Pagliotta C, Uceda Renteria SC, Piralla A, Bergami F, Morandi G, Proto A, Pontiggia F, Risso FM, Bossi A, Ferrari S, Cavalleri V, Servi P, Castiglione A, Spada E, Ceriotti F, Baldanti F, Mosca F, and Pugni L
- Subjects
- Infant, Infant, Newborn, Female, Humans, Pregnancy, Mothers, Prospective Studies, RNA, Viral, SARS-CoV-2 genetics, Infectious Disease Transmission, Vertical, COVID-19, Pregnancy Complications, Infectious diagnosis, Pregnancy Complications, Infectious epidemiology
- Abstract
Objectives: To evaluate the rate of postnatal infection during the first month of life in neonates born to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive mothers during the predominant circulation of the omicron (B.1.1.529) variant., Methods: This prospective, 10-center study enrolled mothers infected by SARS-CoV-2 at delivery and their infants, if both were eligible for rooming-in, between December 2021 and March 2022. Neonates were screened for SARS-CoV-2 RNA at 1 day of life (DOL), 2 to 3 DOL, before discharge, and twice after hospital discharge. Mother-infant dyads were managed under a standardized protocol to minimize the risk of viral transmission. Sequencing data in the study area were obtained from the Italian Coronavirus Disease 2019 Genomic platform. Neonates were included in the final analysis if they were born when the omicron variant represented >90% of isolates., Results: Eighty-two percent (302/366) of mothers had an asymptomatic SARS-CoV-2 infection. Among 368 neonates, 1 was considered infected in utero (0.3%), whereas the postnatal infection rate during virtually exclusive circulation of the omicron variant was 12.1%. Among neonates infected after birth, 48.6% became positive during the follow-up period. Most positive cases at follow-up were detected concurrently with the peak of coronavirus disease 2019 cases in Italy. Ninety-seven percent of the infected neonates were asymptomatic., Conclusions: The risk of early postnatal infection by the SARS-CoV-2 omicron variant is higher than that reported for previously circulating variants. However, protected rooming-in practice should still be encouraged given the paucity of symptoms in infected neonates., (Copyright © 2023 by the American Academy of Pediatrics.)
- Published
- 2023
- Full Text
- View/download PDF
31. Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients.
- Author
-
Zavaglio F, Vitello D, Bergami F, Arena F, Borsani O, Colombo AA, Caldera D, Lilleri D, Cassaniti I, Bernasconi P, and Baldanti F
- Subjects
- Adult, Humans, Cytomegalovirus genetics, T-Lymphocytes, Antiviral Agents therapeutic use, Transplant Recipients, Peptides, Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Background: Human Cytomegalovirus (HCMV) is still one of the major concerning infection in hematopoietic stem cell transplant (HSCT) recipients. Letermovir (LTV) has been recently introduced for HCMV prophylaxis in adult patients who received allogeneic HSCT. However, many aspects related to immune reconstitution need to be further explored. The aim of this study was to define the prognostic role of HCMV-specific T-cell frequency measured at the end of LTV prophylaxis in predicting the risk for clinically significant HCMV infection (i.e. infection requiring antiviral treatment) after the stop of the prophylaxis., Methods: Sixty-six adult patients who underwent allogeneic HSCT were enrolled and HCMV DNAemia was prospectively monitored. Additionally, HCMV-specific T-cell response was evaluated using ELISpot assay against two different antigens (HCMV infected cell lysate and pp65 peptide pool)., Results: Ten patients (15.2%) developed at least one positive HCMV DNAemia episode during LTV prophylaxis, whereas 50/66 (75.8%) patients developed at least one positive HCMV DNA event after LTV prophylaxis. Of note, 25 of them (50%) experienced a clinically significant HCMV infection. The median HCMV-specific T-cell response measured against HCMV lysate but not against pp65 peptide pool was lower in patients who developed HCMV clinically significant infection after prophylaxis. A ROC analysis revealed that the level of 0.04 HCMV-specific T cells/µl should be used as cut-off for development of clinically significant HCMV reactivation after prophylaxis., Conclusion: Assessment of HCMV-specific immunity upon discontinuation of universal prophylaxis with LTV should be considered as a method for identification of patients at risk for clinically significant HCMV infection., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest, (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
32. SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort.
- Author
-
Rizzi M, Tonello S, Brinno C, Zecca E, Matino E, Cittone M, Rizzi E, Casciaro GF, D'Onghia D, Colangelo D, Minisini R, Bellan M, Castello LM, Chiocchetti A, Pirisi M, Rigamonti C, Lilleri D, Zavaglio F, Bergami F, Sola D, and Sainaghi PP
- Subjects
- Humans, SARS-CoV-2, Follow-Up Studies, Prospective Studies, Antiviral Agents, Enzyme Inhibitors, Immunosuppressive Agents adverse effects, COVID-19, Liver Transplantation, Autoimmune Diseases drug therapy
- Abstract
Background: A relevant proportion of immunocompromised patients did not reach a detectable seroconversion after a full primary vaccination cycle against SARS-CoV-2. The effect of different immunosuppressants and the potential risks for SARS-CoV-2 infection in these subjects is largely unknown., Methods: Patients from the Rivalsa prospective, observational cohort study with planned anti SARS-CoV-2 third dose mRNA vaccination between October and December 2021 were asked to participate to this follow-up study. Patients were asked about eventual confirmed positivity to SARS-CoV-2 infection within 6 months from the third dose and to undergo a blood draw to evaluate seroconversion status after the additional vaccine shot., Results: 19 out of 114 patients taking part in the survey developed a confirmed SARS-CoV-2 infection; we identified mycophenolate treatment as an independent predictor of an increased risk of infection even after the third vaccine dose (OR: 5.20, 95% CI: 1.70-20.00, p=0.0053). This result is in agreement with the in vitro evidence that MMF impairs both B and T lymphocytes driven immune responses (reduction both in memory B cells producing anti-spike antibodies and in proliferating CD4+ and CD8+ T cells)., Conclusions: Immunocompromised patients need an additional vaccine administration to reach a detectable seroconversion, thus fostering a more personalized approach to their clinical management. Moreover, patients undergoing mycophenolate treatment show a specific increased infection risk, with respect to other immunosuppressants thus supporting a closer monitoring of their health status., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Rizzi, Tonello, Brinno, Zecca, Matino, Cittone, Rizzi, Casciaro, D’Onghia, Colangelo, Minisini, Bellan, Castello, Chiocchetti, Pirisi, Rigamonti, Lilleri, Zavaglio, Bergami, Sola and Sainaghi.)
- Published
- 2023
- Full Text
- View/download PDF
33. Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects.
- Author
-
Sammartino JC, Cassaniti I, Ferrari A, Piralla A, Bergami F, Arena FA, Paolucci S, Rovida F, Lilleri D, Percivalle E, and Baldanti F
- Subjects
- Humans, Monkeypox virus, Vaccinia virus, Immunity, Smallpox prevention & control, Mpox (monkeypox) epidemiology, Mpox (monkeypox) prevention & control
- Abstract
Monkeypox virus (MPXV) is a zoonotic disease endemic in the rainforest countries of Central and West Africa. Understanding the immune response in zoonosis is fundamental to prevent and contrast viral spreading. MPXV is a close relative of Variola (smallpox) virus and vaccination with vaccinia virus gives approximatively 85% of protection against MPXV. With the emergence of the recent MPXV outbreak, JYNNEOS vaccine has been proposed to individuals at high-risk of exposure. Comparative data on MPXV immune response in vaccinated or infected subjects are still limited. Here we set-up an immunofluorescence method for the evaluation of humoral response elicited by natural infection and healthy vaccinated subjects, including historically smallpox-vaccinated individuals and newly vaccinated subjects. Neutralization assay was also included, and in vaccinated subjects, cell-mediated response was evaluated. We observed that the natural infection produces a strong immune response that can control the disease. In naïve subjects, a second dose boosts the serological response to levels similar to those of the MPXV patients. Last, smallpox-vaccinated controls retain a degree of protection, even after years from vaccination, most visible in the t-cellular response., (© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
34. Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.
- Author
-
Lasagna A, Cassaniti I, Arena F, Bergami F, Percivalle E, Comolli G, Sarasini A, Ferrari A, Cicognini D, Schiavo R, Lo Cascio G, Pedrazzoli P, and Baldanti F
- Subjects
- Humans, BNT162 Vaccine, COVID-19 Vaccines, Follow-Up Studies, SARS-CoV-2, Antibodies, Neutralizing, Immunity, Immunoglobulin G, Antibodies, Viral, mRNA Vaccines, COVID-19 prevention & control, Virus Diseases, Neoplasms therapy
- Abstract
The role and durability of the immunogenicity of the BNT162b2 mRNA vaccine against severe acute respiratory virus 2 (SARS-CoV-2), in cancer patients one year after receiving the third dose have to be elucidated. We have prospectively evaluated the long-term immunogenicity of the third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in 55 patients undergoing active treatment. Neutralizing antibody (NT Ab) titers against Omicron variants and total anti-trimeric S IgG levels were measured one year after the third dose. Heparinized whole-blood samples were used for the assessment of the SARS-CoV-2 interferon-γ release assay (IGRA). Thirty-seven patients (67.3%) showed positive total anti-trimeric S IgG one year after the third dose. Looking at the T-cell response against the spike protein, the frequency of responder patients did not decrease significantly between six and twelve months after the third dose. Finally, less than 20% of cancer patients showed an undetectable NT Ab titer against BA.1 and BA.5 variants of concern (VOCs). Underlying therapies seem to not affect the magnitude or frequency of the immune response. Our work underlines the persistence of humoral and cellular immune responses against BNT162b2 in a cohort of cancer patients one year after receiving the third dose, regardless of the type of underlying therapy.
- Published
- 2023
- Full Text
- View/download PDF
35. Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis.
- Author
-
Monti S, Fornara C, Delvino P, Bartoletti A, Bergami F, Comolli G, Sammartino JC, Biglia A, Bozzalla Cassione E, Cassaniti I, Baldanti F, Lilleri D, and Montecucco C
- Subjects
- Humans, COVID-19 Vaccines, SARS-CoV-2, BNT162 Vaccine, Antibodies, Neutralizing, Vaccination, Immunity, Cellular, Immunity, Humoral, COVID-19 prevention & control, Vasculitis
- Abstract
Objectives: To analyse humoral and cellular immune response to mRNA COVID-19 vaccines in patients with GCA., Methods: Consecutive patients with a diagnosis of GCA receiving two doses of BNT162b2 vaccine were assessed at baseline and 3 weeks from the second vaccine dose. Healthy subjects (n = 51) were included as controls (HC). Humoral response was assessed with Spike-specific IgG antibody response (S-IgG) and neutralizing antibodies (NtAb). Specific T cell response was assessed by enzyme linked immunosorbent spot (ELISpot)., Results: Of 56 included patients with GCA, 44 were eligible after exclusion of previous evidence of COVID-19 and incomplete follow-up. A significant proportion of patients with GCA (91%) demonstrated antibody (S-IgG) response, but this was significantly lower than HCs (100%); P < 0.0001. Neutralizing activity was not detected in 16% of patients with GCA. Antibody titres (S-IgG and NtAb) were significantly lower compared with HCs. Humoral response (S-IgG and NtAb) was significantly hampered by treatment with MTX. Cellular response was lacking in 30% of patients with GCA (vs 0% in HCs; P < 0.0001). Cellular response was significantly influenced by the levels of baseline peripheral T-lymphocytes and by glucocorticoid treatment. Treatment with tocilizumab did not affect any level of the immune response elicited by vaccination., Conclusions: Although patients with GCA apparently achieve a robust antibody seroconversion, there is a significant impairment of the neutralizing activity. MTX significantly reduced all levels of the humoral response. Up to one-third of patients do not develop a cellular immune protection in response to COVID-19 vaccination., (© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
36. Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers.
- Author
-
Bergami F, Arena F, Sammartino JC, Ferrari A, Zavaglio F, Zelini P, Paolucci S, Comolli G, Percivalle E, Lilleri D, Cassaniti I, and Baldanti F
- Abstract
We reported the long-term kinetics of immune response after vaccination and evaluated the immunogenicity after a third dose of mRNA vaccine in 86 healthcare workers. Humoral response was analyzed by measuring anti-spike IgG and SARS-CoV-2 NTAbs titer; cell-mediated response was measured as frequency of IFN-γ producing T-cells and cell proliferation. Memory B cells secreting SARS-CoV-2 RBD-IgG were measured by B-spot assay. At three weeks after the third dose (T4), the frequency of subjects showing NT-Abs titer at the upper detection limit (≥640) was significantly higher than that observed at three weeks after the second dose (26/77; 33.7% vs. 9/77; 11.6%; p = 0.0018). Additionally, at T4, all the subjects reached positive levels of T-cell mediated response (median 110 SFU/10
6 PBMC, IQR 73-231). While the number of IFNγ-producing T-cells decreased between second and third dose administration, the T-cell proliferative response did not decrease but was sustained during the follow-up. Among T-cell subsets, a higher proliferative response was observed in CD4+ than in CD8+ population. Moreover, even if a decline in antibody response was observed between the second and third dose, a sustained persistence of memory B cells was observed. Subsequently, the third dose did not affect the frequency of memory B cells, while it restored or increased the peak antibody levels detected after the second dose.- Published
- 2022
- Full Text
- View/download PDF
37. Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study.
- Author
-
Bergami F, Arena F, Pattonieri EF, Gregorini M, Meloni F, Abelli M, Ticozzelli E, Testa G, Lilleri D, Cassaniti I, and Baldanti F
- Abstract
Since the identification of the new severe acute respiratory syndrome virus 2 (SARS-CoV-2), a huge effort in terms of diagnostic strategies has been deployed. To date, serological assays represent a valuable tool for the identification of recovered COVID-19 patients and for the monitoring of immune response elicited by vaccination. However, the role of T-cell response should be better clarified and simple and easy to perform assays should be routinely introduced. The main aim of this study was to compare a home-made assay for whole blood stimulation with a standardized ELISpot assay design in our laboratory for the assessment of spike-specific T-cell response in vaccinated subjects. Even if a good correlation between the assays was reported, a higher percentage of responder subjects was reported for immunocompromised subjects with ELISpot assay (56%) than home-made whole blood stimulation assay (33%). Additionally, three commercial assays were compared with our home-made assay, reporting a good agreement in terms of both positive and negative results.
- Published
- 2022
- Full Text
- View/download PDF
38. Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients.
- Author
-
Cassaniti I, Gregorini M, Bergami F, Arena F, Sammartino JC, Percivalle E, Soleymaninejadian E, Abelli M, Ticozzelli E, Nocco A, Minero F, Pattonieri EF, Lilleri D, Rampino T, and Baldanti F
- Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has severely impacted on public health, mainly on immunosuppressed patients, including solid organ transplant recipients. Vaccination represents a valuable tool for the prevention of severe SARS-CoV-2 infection, and the immunogenicity of mRNA vaccines has been evaluated in transplanted patients. In this study, we investigated the role of a third dose of the BNT162b2 vaccine in a cohort of kidney transplant recipients, analyzing both humoral and cell-mediated responses. We observed an increased immune response after the third dose of the vaccine, especially in terms of Spike-specific T cell response. The level of seroconversion remained lower than 50% even after the administration of the third dose. Mycophenolate treatment, steroid administration and age seemed to be associated with a poor immune response. In our cohort, 11/45 patients experienced a SARS-CoV-2 infection after the third vaccine dose. HLA antibodies appearance was recorded in 7 out 45 (15.5%) patients, but none of the patients developed acute renal rejection. Further studies for the evaluation of long-term immune responses are still ongoing, and the impact of a fourth dose of the vaccine will be evaluated.
- Published
- 2022
- Full Text
- View/download PDF
39. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
- Author
-
Zuo F, Abolhassani H, Du L, Piralla A, Bertoglio F, de Campos-Mata L, Wan H, Schubert M, Cassaniti I, Wang Y, Sammartino JC, Sun R, Vlachiotis S, Bergami F, Kumagai-Braesch M, Andréll J, Zhang Z, Xue Y, Wenzel EV, Calzolai L, Varani L, Rezaei N, Chavoshzadeh Z, Baldanti F, Hust M, Hammarström L, Marcotte H, and Pan-Hammarström Q
- Subjects
- Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, Humans, RNA, Messenger genetics, Vaccination, Vaccines, Inactivated, Vaccines, Synthetic, mRNA Vaccines, COVID-19 prevention & control, SARS-CoV-2 genetics
- Abstract
The recent emergence of the Omicron variant has raised concerns on vaccine efficacy and the urgent need to study more efficient vaccination strategies. Here we observed that an mRNA vaccine booster in individuals vaccinated with two doses of inactivated vaccine significantly increased the plasma level of specific antibodies that bind to the receptor-binding domain (RBD) or the spike (S) ectodomain (S1 + S2) of both the G614 and the Omicron variants, compared to two doses of homologous inactivated vaccine. The level of RBD- and S-specific IgG antibodies and virus neutralization titers against variants of concern in the heterologous vaccination group were similar to that in individuals receiving three doses of homologous mRNA-vaccine or a boost of mRNA vaccine after infection, but markedly higher than that in individuals receiving three doses of a homologous inactivated vaccine. This heterologous vaccination regime furthermore significantly enhanced the RBD-specific memory B cell response and S1-specific T cell response, compared to two or three doses of homologous inactivated vaccine. Our study demonstrates that mRNA vaccine booster in individuals vaccinated with inactivated vaccines can be highly beneficial, as it markedly increases the humoral and cellular immune responses against the virus, including the Omicron variant., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
40. Immunity to SARS-CoV-2 up to 15 months after infection.
- Author
-
Marcotte H, Piralla A, Zuo F, Du L, Cassaniti I, Wan H, Kumagai-Braesh M, Andréll J, Percivalle E, Sammartino JC, Wang Y, Vlachiotis S, Attevall J, Bergami F, Ferrari A, Colaneri M, Vecchia M, Sambo M, Zuccaro V, Asperges E, Bruno R, Oggionni T, Meloni F, Abolhassani H, Bertoglio F, Schubert M, Calzolai L, Varani L, Hust M, Xue Y, Hammarström L, Baldanti F, and Pan-Hammarström Q
- Abstract
Information concerning the longevity of immunity to SARS-CoV-2 following natural infection may have considerable implications for durability of immunity induced by vaccines. Here, we monitored the SARS-CoV-2 specific immune response in COVID-19 patients followed up to 15 months after symptoms onset. Following a peak at day 15-28 postinfection, the IgG antibody response and plasma neutralizing titers gradually decreased over time but stabilized after 6 months. Compared to G614, plasma neutralizing titers were more than 8-fold lower against variants Beta, Gamma, and Delta. SARS-CoV-2-specific memory B and T cells persisted in the majority of patients up to 15 months although a significant decrease in specific T cells, but not B cells, was observed between 6 and 15 months. Antiviral specific immunity, especially memory B cells in COVID-19 convalescent patients, is long-lasting, but some variants of concern may at least partially escape the neutralizing activity of plasma antibodies., Competing Interests: The other authors declare no competing interests., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
41. Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine in vulnerable patients with giant cell arteritis.
- Author
-
Delvino P, Bartoletti A, Cassaniti I, Bergami F, Lilleri D, Baldanti F, Bozzalla Cassione E, Biglia A, Montecucco C, and Monti S
- Subjects
- Aged, COVID-19 prevention & control, Female, Humans, Male, Pandemics, COVID-19 Vaccines immunology, Giant Cell Arteritis drug therapy, Immunogenicity, Vaccine immunology, Immunosuppressive Agents therapeutic use
- Published
- 2022
- Full Text
- View/download PDF
42. Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study.
- Author
-
Cassaniti I, Bergami F, Percivalle E, Gabanti E, Sammartino JC, Ferrari A, Adzasehoun KMG, Zavaglio F, Zelini P, Comolli G, Sarasini A, Piralla A, Ricciardi A, Zuccaro V, Maggi F, Novazzi F, Simonelli L, Varani L, Lilleri D, and Baldanti F
- Subjects
- Antibodies, Viral, BNT162 Vaccine, COVID-19 Vaccines, Health Personnel, Humans, Vaccination, Vaccines, Synthetic, mRNA Vaccines, COVID-19, SARS-CoV-2
- Abstract
Objectives: To assess the humoral and cell-mediated response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited by the mRNA BNT162b2 vaccine in SARS-CoV-2-experienced and -naive subjects against a reference strain and SARS-CoV-2 variants., Methods: The humoral response (including neutralizing antibodies) and T-cell-mediated response elicited by BNT162b2 vaccine in 145 healthcare workers (both naive and positive for previous SARS-CoV-2 infection) were evaluated. In a subset of subjects, the effect of SARS-CoV-2 variants on antibody level and cell-mediated response was also investigated., Results: Overall, 125/127 naive subjects (98.4%) developed both neutralizing antibodies and specific T cells after the second dose of vaccine. Moreover, the antibody and T-cell responses were effective against viral variants since SARS-CoV-2 NT Abs were still detectable in 55/68 (80.9%) and 25/29 (86.2%) naive subjects when sera were challenged against β and δ variants, respectively. T-cell response was less affected, with no significant difference in the frequency of responders (p 0.369). Of note, two doses of vaccine were able to elicit sustained neutralizing antibody activity against all the SARS-CoV-2 variants tested in SARS-CoV-2-experienced subjects., Conclusions: BNT162b2 vaccine elicited a sustained humoral and cell-mediated response in immunocompetent subjects after two-dose administration of the vaccine, and the response seemed to be less affected by SARS-CoV-2 variants, the only exceptions being the β and δ variants. Increased immunogenicity, also against SARS-CoV-2 variant strains, was observed in SARS-CoV-2-experienced subjects. These results suggest that triple exposure to SARS-CoV-2 antigens might be proposed as valuable strategy for vaccination campaigns., (Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
43. Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant.
- Author
-
Cassaniti I, Bergami F, Arena F, Sammartino JC, Ferrari A, Zavaglio F, Curti I, Percivalle E, Meloni F, Pandolfi L, Pellegrini C, Turco A, Seminari E, Pattonieri EF, Gregorini M, Rampino T, Sarasini A, Lilleri D, and Baldanti F
- Abstract
The immunogenicity of severe acute respiratory syndrome 2 virus (SARS-CoV-2) vaccines in immunocompromised patients remains to be further explored. Here, we evaluated the immunogenicity elicited by complete vaccination with BNT162b2 vaccine in solid organ transplant recipients (SOTRs). A cohort of 110 SOTRs from Northern Italy were vaccinated with two doses of BNT162b2 mRNA vaccine and prospectively monitored at baseline and after 42 days. Both SARS-CoV-2 naïve and recovered subjects were included. Humoral response elicited by vaccination, including SARS-CoV-2 neutralizing antibodies (SARS-CoV-2 NT Abs), was evaluated; additionally, ex-vivo ELISpot assay was performed for the quantification of Spike-specific T-cell response. Results were compared with those obtained in a cohort of healthy subjects. In a subset of patients, humoral and T-cell responses against delta variant were also evaluated. Less than 20% of transplanted subjects developed a positive humoral and cell-mediated response after complete vaccination schedule. Overall, median levels of immune response elicited by vaccination were significantly lower with respect to controls in SARS-CoV-2 naïve transplant, but not in SARS-CoV-2 recovered transplanted patients. Additionally, a significant impairment of both humoral and cell-mediated response was observed in mycophenolate-treated patients. Positive delta-SARS-CoV-2 NT Abs levels were detected in almost all the SARS-CoV-2 recovered subjects but not in previously uninfected patients. Our study supports previous observations of a low level of seroconversion after vaccination in transplanted patients.
- Published
- 2021
- Full Text
- View/download PDF
44. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers.
- Author
-
Rovida F, Cassaniti I, Paolucci S, Percivalle E, Sarasini A, Piralla A, Giardina F, Sammartino JC, Ferrari A, Bergami F, Muzzi A, Novelli V, Meloni A, Cutti S, Grugnetti AM, Grugnetti G, Rona C, Daglio M, Marena C, Triarico A, Lilleri D, and Baldanti F
- Subjects
- Antibodies, Viral blood, BNT162 Vaccine, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 virology, COVID-19 Nucleic Acid Testing statistics & numerical data, Case-Control Studies, Female, Humans, Immunization Schedule, Incidence, Male, Prospective Studies, RNA, Viral genetics, RNA, Viral isolation & purification, SARS-CoV-2 genetics, SARS-CoV-2 immunology, SARS-CoV-2 isolation & purification, Severity of Illness Index, Asymptomatic Infections epidemiology, COVID-19 diagnosis, COVID-19 Vaccines administration & dosage, Health Personnel statistics & numerical data, SARS-CoV-2 pathogenicity
- Abstract
Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects, with a 100-day cumulative incidence of 0.93%. Vaccine protection against acquisition of SARS-CoV-2 infection is 83% (95%CI: 58-93%) in the overall population and 93% (95%CI: 69-99%) in SARS-CoV-2-experienced subjects, when compared with a non-vaccinated control group from the same Institution, in which SARS-CoV-2 infection occurs in 20/346 subjects (100-day cumulative incidence: 5.78%). The infection is symptomatic in 16 (48%) vaccinated subjects vs 17 (85%) controls (p = 0.01). All analyzed patients, in whom the amount of viral RNA was sufficient for genome sequencing, results infected by the alpha variant. Antibody and T-cell responses are not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, is observed in two (6.1%) cases. This real-world data support the protective effect of BNT162b2 vaccine. A triple antigenic exposure, such as two-dose vaccine schedule in experienced subjects, may confer a higher protection., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
45. Impact of Viral Decontamination Method on Cytokine Profile of COVID-19 Patients.
- Author
-
Magrì D, Navarro A, Bergami F, Percivalle E, Ferrari A, Lettieri T, Calzolai L, Piralla A, Baldanti F, and Gioria S
- Abstract
COVID-19 related morbidity and mortality have been often attributed to an exaggerated immune response. The role of cytokines and chemokines in COVID-19 and their contributions to illness severity are known, and thus their profiling from patient bronchoalveolar lavage (BAL) samples would help in understanding the disease progression. To date, limited studies have been performed on COVID-19 BAL samples, as the manipulation of such specimens (potentially containing live viruses) requires several laboratorial precautions, such as personnel training and special equipment, a requirement that not all laboratories can fulfil. Here, we assessed two fast and easily applicable methods (ultrafiltration and ultraviolet-C irradiation) for their impact on viral load removal or inactivation, respectively and on cytokine profiles preservation. Eight samples of BAL fluids from SARS-CoV2 patients with high viral load were tested. For both methods, complete removal was confirmed by lack of viral replication in Vero E6 cells and by RT-qPCR. Although both methods showed to remove completely the active SARS-CoV2 viral load, only UVC treatment has little or no quantitative effect on total cytokines/chemokines measurements, however cytokines profile and relative ratios are preserved or minimally altered when compared data obtained by the two different decontamination methods. Sample preparation and manipulation can greatly affect the analytical results; therefore, understanding if changes occurred after sample processing is of outmost importance for reliable data and can be useful to improve clinical practice.
- Published
- 2021
- Full Text
- View/download PDF
46. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay.
- Author
-
Cassaniti I, Percivalle E, Bergami F, Piralla A, Comolli G, Bruno R, Vecchia M, Sambo M, Colaneri M, Zuccaro V, Benazzo M, Robotti C, Calastri A, Maiorano E, Ferrari A, Cambiè G, and Baldanti F
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Neutralizing blood, Antibodies, Viral blood, Antigens, Viral immunology, Cohort Studies, Convalescence, Cross Reactions, Enzyme-Linked Immunospot Assay, Female, Follow-Up Studies, Humans, Immunity, Cellular, Male, Middle Aged, Young Adult, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, COVID-19 immunology, Immunologic Memory, SARS-CoV-2 immunology
- Abstract
Objectives: SARS-CoV-2 T-cell response characterization represents a crucial issue for defining the role of immune protection against COVID-19. The aim of the study was to assess the SARS-CoV-2 T-cell response in a cohort of COVID-19 convalescent patients and in a group of unexposed subjects., Methods: SARS-CoV-2 T-cell response was quantified from peripheral blood mononuclear cells (PBMCs) of 87 COVID-19 convalescent subjects (range 7-239 days after symptom onset) and 33 unexposed donors by ex vivo ELISpot assay. Follow-up of SARS-CoV-2 T-cell response was performed in ten subjects up to 12 months after symptom onset. The role of SARS-CoV-2 specific CD4 and CD8 T cells was characterized in a group of COVID-19 convalescent subjects. Moreover, neutralizing antibodies were determined in serum samples., Results: In 14/33 (42.4%) unexposed donors and 85/87 (97.7%) COVID-19 convalescent subjects a positive result for at least one SARS-CoV-2 antigen was observed. A positive response was observed up to 12 months after COVID-19 infection (median 246 days after symptom onset; range 118-362 days). Of note, SARS-CoV-2 T-cell response seems to be mainly mediated by CD4 T cells. A weak positive correlation was observed between Spike-specific T-cell response and neutralizing antibody titre (p 0.0028; r
2 = 0.2891) and positive SARS-CoV-2 T-cell response was observed in 8/9 (88.9%) COVID-19 convalescent subjects with undetectable SARS-CoV-2 neutralizing antibodies., Discussion: Cross-reactive SARS-CoV-2 T-cell response in uninfected patients may be due to previous infections with other common coronaviruses. Our data suggest that long-term SARS-CoV-2 T-cell response might accompany a waning humoral response., (Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
47. Intensive short-term dynamic psychotherapy provided by novice psychotherapists: effects on symptomatology and psychological structure in patients with anxiety disorders.
- Author
-
Rocco D, Calvo V, Agrosi V, Bergami F, Busetto LM, Marin S, Pezzetta G, Rossi L, Zuccotti L, and Abbass A
- Abstract
This study examines the effectiveness of psychotherapy provided by novice therapists, in an attempt to clarify the controversial relationship between treatment effectiveness and therapist experience. To achieve this, we examined the short- and long-term effectiveness of intensive short-term dynamic psychotherapy (ISTDP) in the treatment of patients with the Diagnostic and Statistical Manual of Mental Disorder, IV edition - Text Revision anxiety disorders, as provided by novice psychology trainees. Twenty-two patients with anxiety disorders were provided ISTDP. Patients improved significantly on all outcome indices, including the global assessment of functioning, the symptom checklist and the inventory of interpersonal problems, at the end of the treatment and at 6 and 12 month follow-up. In addition to these results, there was marked structural personality change as evidenced by ratings on the Shedler Westen assessment procedure (SWAP-200), at the same assessment moments; the SWAP-200 psychological health index score showed a meaningful increase in adaptive psychological resources and capacities, while the mean number of personality diagnoses decreased from the beginning to the end of therapy, and all patients maintaining their gains in 6-12 month follow-up. We conclude that ISTDP provided by novice psychotherapists is efficacious in bringing broad and in-depth change to pathology that can perpetuate anxiety disorders and other psychiatric conditions., (©Copyright: the Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
48. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection.
- Author
-
Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, Braesch-Andersen S, Cassaniti I, Percivalle E, Sarasini A, Bergami F, Di Martino R, Colaneri M, Vecchia M, Sambo M, Zuccaro V, Bruno R, Sachs M, Oggionni T, Meloni F, Abolhassani H, Bertoglio F, Schubert M, Byrne-Steele M, Han J, Hust M, Xue Y, Hammarström L, Baldanti F, Marcotte H, and Pan-Hammarström Q
- Subjects
- Antibodies, Viral, Humans, Immunoglobulin A, Immunoglobulin G, T-Lymphocytes, COVID-19, SARS-CoV-2
- Abstract
Background: Monitoring the adaptive immune responses during the natural course of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection provides useful information for the development of vaccination strategies against this virus and its emerging variants. We thus profiled the serum anti-SARS-CoV-2 antibody (Ab) levels and specific memory B and T cell responses in convalescent coronavirus disease 2019 (COVID-19) patients., Methods: A total of 119 samples from 88 convalescent donors who experienced mild to critical disease were tested for the presence of elevated anti-spike and anti-receptor binding domain Ab levels over a period of 8 months. In addition, the levels of SARS-CoV-2 neutralizing Abs and specific memory B and T cell responses were tested in a subset of samples., Findings: Anti-SARS-CoV-2 Abs were present in 85% of the samples collected within 4 weeks after the onset of symptoms in COVID-19 patients. Levels of specific immunoglobulin M (IgM)/IgA Abs declined after 1 month, while levels of specific IgG Abs and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. Anti-SARS-CoV-2 IgG Abs were still present, although at a significantly lower level, in 80% of the samples collected at 6-8 months after symptom onset. SARS-CoV-2-specific memory B and T cell responses developed with time and were persistent in all of the patients followed up for 6-8 months., Conclusions: Our data suggest that protective adaptive immunity following natural infection of SARS-CoV-2 may persist for at least 6-8 months, regardless of disease severity. Development of medium- or long-term protective immunity through vaccination may thus be possible., Funding: This project was supported by the European Union's Horizon 2020 research and innovation programme (ATAC, no. 101003650), the Italian Ministry of Health (Ricerca Finalizzata grant no. GR-2013-02358399), the Center for Innovative Medicine, and the Swedish Research Council. J.A. was supported by the SciLifeLab/KAW national COVID-19 research program project grant 2020., Competing Interests: S.B.-A. is a member of the advisory board of Mabtech AB. The other authors declare no competing interests., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
49. Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?
- Author
-
Piralla A, Ricchi M, Cusi MG, Prati P, Vicari N, Scarsi G, Gandolfo C, Anichini G, Terrosi C, Percivalle E, Vecchio Nepita E, Bergami F, Tallarita M, Di Martino R, Ferrari A, Rovida F, Lunghi G, Schiavo R, and Baldanti F
- Subjects
- Adult, COVID-19 diagnosis, COVID-19 transmission, COVID-19 Testing, Disease Progression, Female, Humans, Male, Middle Aged, Nose virology, Prospective Studies, Real-Time Polymerase Chain Reaction, SARS-CoV-2 genetics, SARS-CoV-2 physiology, Time Factors, Viral Load, Young Adult, COVID-19 virology, Quarantine, RNA, Viral genetics, SARS-CoV-2 isolation & purification
- Abstract
Real-time reverse transcription PCR is currently the most sensitive method to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Defining whether a patient could be contagious or not contagious in the presence of residual SARS-CoV-2 RNA is of extreme importance in the context of public health. In this prospective multicenter study, virus isolation was prospectively attempted in 387 nasal swabs from clinically recovered patients showing low viral load (quantification cycle, Cq, value greater than 30). The median Cq value was 36.8 (range 30.0-39.4). Overall, a cytopathic effect was detected in nine samples, corresponding to a culture positivity rate of 2.3% (9/387). The results of this study help to dissect true virus replication and residual viral RNA detection in recovered patients., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
50. Analysis of the Contribution of Hemocytes and Autophagy to Drosophila Antiviral Immunity.
- Author
-
Lamiable O, Arnold J, de Faria IJDS, Olmo RP, Bergami F, Meignin C, Hoffmann JA, Marques JT, and Imler JL
- Subjects
- Animals, Apoptosis, Autophagy-Related Protein 7 genetics, Autophagy-Related Protein 7 metabolism, Cell Line, Drosophila cytology, Drosophila genetics, Drosophila Proteins genetics, Drosophila Proteins metabolism, RNA Interference, Sindbis Virus immunology, Vesicular stomatitis Indiana virus immunology, Virus Replication, Autophagy, DNA Viruses immunology, Drosophila immunology, Drosophila virology, Hemocytes immunology, Phagocytosis, RNA Viruses immunology
- Abstract
Unlabelled: Antiviral immunity in the model organism Drosophila melanogaster involves the broadly active intrinsic mechanism of RNA interference (RNAi) and virus-specific inducible responses. Here, using a panel of six viruses, we investigated the role of hemocytes and autophagy in the control of viral infections. Injection of latex beads to saturate phagocytosis, or genetic depletion of hemocytes, resulted in decreased survival and increased viral titers following infection with Cricket paralysis virus (CrPV), Flock House virus (FHV), and vesicular stomatitis virus (VSV) but had no impact on Drosophila C virus (DCV), Sindbis virus (SINV), and Invertebrate iridescent virus 6 (IIV6) infection. In the cases of CrPV and FHV, apoptosis was induced in infected cells, which were phagocytosed by hemocytes. In contrast, VSV did not trigger any significant apoptosis but we confirmed that the autophagy gene Atg7 was required for full virus resistance, suggesting that hemocytes use autophagy to recognize the virus. However, this recognition does not depend on the Toll-7 receptor. Autophagy had no impact on DCV, CrPV, SINV, or IIV6 infection and was required for replication of the sixth virus, FHV. Even in the case of VSV, the increases in titers were modest in Atg7 mutant flies, suggesting that autophagy does not play a major role in antiviral immunity in Drosophila Altogether, our results indicate that, while autophagy plays a minor role, phagocytosis contributes to virus-specific immune responses in insects., Importance: Phagocytosis and autophagy are two cellular processes that involve lysosomal degradation and participate in Drosophila immunity. Using a panel of RNA and DNA viruses, we have addressed the contribution of phagocytosis and autophagy in the control of viral infections in this model organism. We show that, while autophagy plays a minor role, phagocytosis contributes to virus-specific immune responses in Drosophila This work brings to the front a novel facet of antiviral host defense in insects, which may have relevance in the control of virus transmission by vector insects or in the resistance of beneficial insects to viral pathogens., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.